Terminated PHASE2 INTERVENTIONAL NCT00003729

Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia

Phase II Study of Fludarabine + Idarubicin + Aracytine in Refractory or Relapsed ALL in Children

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Leukemia

Interventions cytarabine fludarabine phosphate idarubicin

Updated 6 times since 2017 Last updated: Sep 20, 2012 Started: Dec 31, 1998 Primary completion: Apr 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

low accrual

Other terminated trials from European Organisation for Research and Treatment of Cancer - EORTC

See all terminations from European Organisation for Research and Treatment of Cancer - EORTC

Other Leukemia trials with similar outcome

Browse all Leukemia trials

This PHASE2 trial investigates Leukemia and is currently terminated or withdrawn. European Organisation for Research and Treatment of Cancer - EORTC leads this study, which shows 6 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Dec 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Organisation for Research and Treatment of Cancer - EORTC

Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France , Antwerp, Belgium , Besançon, France , Brussels (Bruxelles), Belgium , Caen, France , Ghent (Gent), Belgium , Grenoble, France , Leuven, Belgium , Liege (Luik), Belgium , Lille, France and 11 more locations